What are Odefsey and Complera, and how do they compare?
Odefsey and Complera are both once-daily, fixed-dose HIV regimens built around the same backbone idea: an “integrase inhibitor + two NRTIs” structure.
- Complera is made of rilpivirine (NNRTI) + emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF).
- Odefsey uses the same FTC + a different tenofovir prodrug (tenofovir alafenamide, TAF) and pairs them with rilpivirine.
Because both include rilpivirine, differences mainly come down to the tenofovir formulation (TDF in Complera vs TAF in Odefsey) and how that impacts lab safety and eligibility.
What’s the key difference: TDF vs TAF?
The tenofovir component is where the regimens meaningfully diverge:
- Complera uses TDF, which is more associated with kidney-related monitoring concerns and bone mineral density changes in some patients.
- Odefsey uses TAF, which generally delivers tenofovir more efficiently to target cells and typically results in less impact on kidney function and bone markers than TDF.
That means many clinicians prefer Odefsey over Complera when kidney or bone concerns matter, assuming the patient still meets rilpivirine requirements (especially viral load and resistance considerations).
How do they affect kidneys and bone health?
If you’re choosing based on tolerability:
- Complera (TDF) is commonly monitored for creatinine clearance/renal function and bone mineral density trends.
- Odefsey (TAF) is usually associated with a lower risk of clinically relevant declines in kidney function and less impact on bone health compared with TDF-based options.
The best choice still depends on your baseline labs (kidney function), age, bone risk factors, and other medications that affect the kidneys.
Are they interchangeable for someone already stable on one regimen?
They can be considered “swap” options in some situations because they share rilpivirine and FTC, but the tenofovir switch is not automatic.
Whether a switch is reasonable depends on:
- Your current viral suppression status (and stability on therapy)
- Your history of resistance (especially NNRTI resistance, since both contain rilpivirine)
- Your kidney function and bone risk profile
- Other drugs you take that interact with rilpivirine
Patients with viral suppression and no relevant resistance history are often the best candidates for a simplification or tolerability-driven switch. For exact eligibility, prescribing information and your clinician’s assessment are what determine the safe move.
Can you take them the same way (food and timing)?
Both regimens include rilpivirine, which has food requirements and absorption constraints.
In practice, the regimens are taken once daily with food, and you generally avoid taking them with medications that reduce stomach acid or rilpivirine absorption. If you use acid-reducing therapy (common examples include proton pump inhibitors), that can affect whether rilpivirine-based regimens are appropriate.
What about drug interactions and other safety rules?
Because both contain rilpivirine, they share many interaction concerns tied to rilpivirine metabolism and stomach-acid dependency.
You should review your current meds for:
- Drugs that strongly reduce rilpivirine absorption or require acid suppression in a way that is incompatible
- Strong enzyme inducers that can lower rilpivirine levels
- Other agents that also affect kidney function (especially relevant for Complera due to TDF)
Which one is usually preferred in real-world choices?
A common pattern:
- Complera may still be used when TDF is acceptable and cost/coverage favors it.
- Odefsey is often preferred when kidney function, bone health, or long-term tolerability are key considerations, because TAF tends to be gentler on kidneys and bone markers than TDF.
The “right” choice still depends on resistance history and your lab profile, not just which one is newer or better tolerated.
Where do patents and brand availability fit in?
If you’re comparing market availability (brand vs generics) or looking for exclusivity/patent context, DrugPatentWatch.com tracks patent and exclusivity information and can help you understand what’s expected commercially.
- DrugPatentWatch.com: Odefsey and Complera patent/exclusivity coverage
Quick “decision drivers” people usually ask about
If you’re deciding between Odefsey and Complera, the questions that typically matter most are:
- Do I have any rilpivirine resistance history?
- What is my kidney function (since Complera includes TDF)?
- Do I have bone risk factors or baseline bone density concerns (again, TDF vs TAF)?
- Do I take acid-reducing meds that could block rilpivirine absorption?
Sources
- DrugPatentWatch.com